Kartos Therapeutics is a privately held, clinical-stage biopharmaceutical enterprise dedicated to developing advanced precision oncology treatments, specifically focusing on best-in-class targeted inhibitors for hematologic malignancies and cancers. The organization maintains its primary corporate headquarters and research operations in Redwood City, California, situated within the dynamic biotechnology and life sciences hub of the San Francisco Bay Area. Additionally, the company maintains a secondary strategic office presence in Bellevue, Washington, allowing it to collaborate closely with leading clinical investigators, scientific researchers, and oncology treatment centers across multiple major geographic regions in the United States.